Safety and immunogenicity of VGX-3100 formulations in a healthy young adult population

• Main Authors: Rebecca K. Hollenberg (Author), Diane R. Krieger (Author), Robert Samuels (Author), Kim Kraynyak (Author), Albert Sylvester (Author), Matthew Morrow (Author), Jean Boyer (Author), Michael Dallas (Author), Prakash K. Bhuyan (Author)
• Format: Book
• Published: Taylor & Francis Group, 2020-06-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

HPV remains the most common sexually transmitted disease worldwide, despite improvements in awareness, screening, prophylactic vaccination uptake, and surgical treatment. VGX-3100 is an immunotherapy that uses electroporation to introduce DNA encoding for modified HPV-16 and HPV-18, E6-and E7 protei...